Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

CardioDx Receives CAP Accreditation

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
CAP accreditation is awarded to clinical laboratories meeting the highest standards of excellence in quality laboratory practices.

CardioDx, Inc. announced its onsite clinical laboratory has received accreditation from the College of American Pathologists (CAP), which is awarded to facilities that meet the highest standards of excellence in quality laboratory practices.  This recognition adds to the certification of the clinical laboratory previously received from the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Improvements Amendment (CLIA) and to the licensure issued by the New York State Department of Health. CardioDx offers Corus® CAD, the only clinically validated gene expression blood test for evaluating patients with signs and symptoms suggestive of obstructive coronary artery disease (CAD), nationally through its accredited laboratory in Palo Alto, CA.

The CAP Laboratory Accreditation Program is an internationally recognized program and the only one of its kind to utilize teams of practicing laboratory professionals as inspectors. During the accreditation process, inspectors examine the clinical laboratory's records and quality control procedures, as well as the laboratory's equipment, facilities, safety program and overall laboratory management to ensure it meets CAP's stringent requirements. The goal of the CAP program is to improve patient safety by advancing the quality of pathology and laboratory services through education and rigorous standards, which meet or exceed regulatory requirements. CMS has granted the CAP Laboratory Accreditation Program deeming authority. The program is also recognized by the Joint Commission, and can be used to meet many state certification requirements.

"CardioDx is proud to join an outstanding group of more than 7,300 laboratories worldwide that have received CAP accreditation," said David Levison , President and CEO of CardioDx. "This important milestone reflects our commitment to providing the highest quality standards for our clinicians and their patients."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos